~~<i id='13273856E0'><strike id='13273856E0'><tt id='13273856E0'><pre id='13273856E0'></pre></tt></strike></i>~~

Home» focus» fashion

fashion

author：entertainment 2025-10-02 04:29:52 Page View：563

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Elizabeth Holmes on track for early release from her 11
Next article： Medicare details structure of new drug price negotiation program

comprehensive

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Study: Pain burden is higher in Black NFL players than white ones

JuliusThomas,nowpursuinghisPh.D.inpsychology,playingfortheMiamiDolphinsin2017.AdrianKraus/APIt’stobe

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Beach reads and more: STAT's 2023 summer book list

AlexHogan/STATWithsummerinfullswing,it’sagreattimetotuckintoanewbookorpodcast.Whetheryou’relookingfo